Literature DB >> 19586413

Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.

Thomas P Lodise1, Nimish Patel, Ben M Lomaestro, Keith A Rodvold, George L Drusano.   

Abstract

BACKGROUND: Data suggest that higher doses of vancomycin can increase the risk of nephrotoxicity. No study has been undertaken to determine the pharmacodynamic index (ie, the area under the curve [AUC] or the trough value) that best describes the relationship between vancomycin exposure and onset of nephrotoxicity.
METHODS: A retrospective study was conducted among patients who received vancomycin for a suspected or proven gram-positive infection during the period from 1 January 2005 through 31 December 2006 at Albany Medical Center Hospital. Patients were included in our study if they (1) were > or =18 years old, (2) had an absolute neutrophil count of > or =1000 cells/mm(3), (3) received vancomycin for >48 h, (4) had 1 vancomycin trough level collected within 96 h of vancomycin therapy, and (5) had a baseline serum creatinine level of <2.0 mg/dL. Patients were excluded if they (1) had a diagnosis of cystic fibrosis, (2) received intravenous contrast dye within 7 days of starting vancomycin or during therapy, or (3) required vasopressor support during therapy. Demographics, comorbid conditions, and treatment data were collected. The highest observed vancomycin trough value within 96 h of initiation of vancomycin therapy and the estimated vancomycin AUC were analyzed as measures of vancomycin exposure. The vancomycin AUC value from 0 to 24 h at steady state (in units of mg x h/L) for each patient was estimated by use of the maximum a posteriori probability Bayesian procedure in ADAPT II. Nephrotoxicity was defined as an increase in serum creatinine level of 0.5 mg/dL or 50%, whichever was greater, following initiation of vancomycin therapy. Logistic and Cox proportional hazards regression models identified the vancomycin pharmacodynamic index that best describes the relationship between vancomycin exposure and toxicity.
RESULTS: During the study period, 166 patients met the inclusion criteria. Both initial vancomycin trough values and 0-24-h at steady state AUC values were associated with nephrotoxicity in the bivariate analyses. However, the vancomycin trough value, modeled as a continuous variable, was the only vancomycin exposure variable associated with nephrotoxicity in the multivariate analyses.
CONCLUSIONS: The results indicate that a vancomycin exposure-toxicity response relationship exists. The vancomycin trough value is the pharmacodynamic index that best describes this association.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19586413     DOI: 10.1086/600884

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  155 in total

1.  Localized mandibular infection affects remote in vivo bioreactor bone generation.

Authors:  Emma Watson; Brandon T Smith; Mollie M Smoak; Alexander M Tatara; Sarita R Shah; Hannah A Pearce; Katie J Hogan; Jonathan Shum; James C Melville; Issa A Hanna; Nagi Demian; Joseph C Wenke; George N Bennett; Jeroen J J P van den Beucken; John A Jansen; Mark E Wong; Antonios G Mikos
Journal:  Biomaterials       Date:  2020-06-23       Impact factor: 12.479

2.  Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.

Authors:  Anthony M Nicasio; Jürgen B Bulitta; Thomas P Lodise; Rebecca E D'Hondt; Robert Kulawy; Arnold Louie; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 3.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.

Authors:  Sepideh Elyasi; Hossein Khalili; Simin Dashti-Khavidaki; Amirhooshang Mohammadpour
Journal:  Eur J Clin Pharmacol       Date:  2012-03-13       Impact factor: 2.953

4.  Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Authors:  Katsuhiro Miura; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Masashi Sakagami; Shimon Ohtake; Sumiko Kobayashi; Atsuko Hojo; Daisuke Kurita; Yujin Kobayashi; Machiko Kusuda; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
Journal:  Int J Hematol       Date:  2015-12-29       Impact factor: 2.490

Review 5.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

6.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

7.  Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Authors:  Nathaniel J Rhodes; Walter C Prozialeck; Thomas P Lodise; Natarajan Venkatesan; J Nicholas O'Donnell; Gwendolyn Pais; Cameron Cluff; Peter C Lamar; Michael N Neely; Anil Gulati; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  Vancomycin-Associated Cast Nephropathy.

Authors:  Yosu Luque; Kevin Louis; Chantal Jouanneau; Sandrine Placier; Emmanuel Esteve; Dominique Bazin; Eric Rondeau; Emmanuel Letavernier; Alice Wolfromm; Clément Gosset; Anna Boueilh; Maren Burbach; Perrine Frère; Marie-Christine Verpont; Sophie Vandermeersch; Dominique Langui; Michel Daudon; Vincent Frochot; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2017-01-12       Impact factor: 10.121

9.  Impact of Pharmacy Practice Model Expansion on Pharmacokinetic Services: Optimization of Vancomycin Dosing and Improved Patient Safety.

Authors:  Zhe Han; Natasha N Pettit; Emily M Landon; Benjamin D Brielmaier
Journal:  Hosp Pharm       Date:  2017-04

Review 10.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.